Research
Hormonal
Bariatric surgery is the most effective treatment for both obesity and T2DM, offering benefits beyond weight loss by recovering islet function and normalizing gut hormones.
For severe obesity and T2DM, bariatric surgery is currently the most effective treatment, working by restoring gut hormones (GLP-1, PYY) and beta-cell function, not just by reducing stomach size. It should be considered when lifestyle changes fail, despite surgical risks.
GoodSupportsHIGH confidence
Surgical procedures, whether endoscopic or non-endoscopic, have made their names among patients suitable for different approaches... bariatric surgeries are beneficial far beyond contributing to weight loss but also recovering islet function by reversing metabolic disorders and normalizing the levels of glucagon-like peptide 1 (GLP-1) and peptide YY (PYY).
Why this rating
Review paper citing clinical findings and surgical outcomes.
Source
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Rexiati Ruze et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1161521
narrative_reviewCited 688×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Certain anti-diabetic medications, specifically insulin, can increase body weight, creating a conflict in treating obesity and T2DM simultaneously.Strong
- Obesity accelerates the loss of pancreatic beta-cell function and insulin sensitivity through ectopic adipose expansion, systemic low-grade inflammation, and lipotoxicity, leading to Type 2 Diabetes Mellitus (T2DM).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →